Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Avi Kapoor

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Analyst,Woman,Working,With,Information,Database,To,Analyze,Marketing,And

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

The company posted quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $776.133 million which missed the analyst consensus estimate of $780.629 million.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.